Cancer can cause rashes through several distinct pathways, and some skin changes serve as the first visible clue that a malignancy is developing inside the body. These rashes fall into broad categories: paraneoplastic syndromes, where an internal tumor triggers a skin reaction at a distance; direct infiltration, where cancer cells physically invade the skin; cancers that start in the skin itself but look like ordinary rashes; and skin reactions caused by cancer treatments. Recognizing which patterns deserve urgent attention and which are benign is genuinely tricky, even for doctors.
How an Internal Cancer Can Trigger a Rash
Paraneoplastic dermatoses are skin conditions caused not by cancer cells in the skin but by substances the tumor releases or by immune responses the tumor provokes. The cancer might be in the lung, stomach, pancreas, or blood, yet the rash shows up on the surface of the body. Several of these conditions are well documented, including dermatomyositis, erythema gyratum repens, malignant acanthosis nigricans, necrolytic migratory erythema, and paraneoplastic pemphigus.1PubMed Central. Life-threatening paraneoplastic cutaneous syndromes What makes them clinically important is that the rash can appear months before the cancer is found by any other means. In some cases, the skin change is the reason the cancer gets caught at all.
Not every unexplained rash signals cancer. The vast majority of rashes are caused by infections, allergies, autoimmune conditions, or simple irritation. But a handful of specific patterns have strong enough associations with malignancy that dermatologists treat them as red flags requiring a cancer workup. The sections below walk through the main types.
Dermatomyositis
Dermatomyositis is an inflammatory muscle disease that also produces distinctive skin findings: a violet-colored rash on the eyelids (sometimes called a heliotrope rash), scaly patches over the knuckles (Gottron papules), and reddened skin across the chest, shoulders, and back. Muscle weakness, particularly in the hips and shoulders, usually accompanies the skin changes.
The cancer connection is substantial. People with dermatomyositis face roughly a four-and-a-half-fold higher risk of developing a malignancy compared to the general population.2PubMed Central. A Study on Dermatomyositis and the Relation to Malignancy The cancers most commonly linked to it include ovarian, lung, pancreatic, stomach, and colorectal cancers. Because of this association, current practice guidelines recommend cancer screening for anyone newly diagnosed with dermatomyositis, especially adults over 40. The skin findings sometimes improve when the underlying tumor is successfully treated, reinforcing the idea that the tumor itself is driving the immune reaction in the skin.
Erythema Gyratum Repens
If you looked up images of erythema gyratum repens, you would not forget them. The rash creates concentric, wavy, “wood-grain” bands across the torso and limbs that shift and migrate over days. It is rare, and it is one of the most cancer-specific rashes known. The condition is most frequently linked to lung, esophageal, and breast cancers.3PubMed Central. Erythema gyratum repens: a rare paraneoplastic rash Prompt identification matters because the rash often shows up months before the cancer diagnosis, giving doctors a potential head start on detection.4PubMed Central. Erythema Gyratum Repens Associated With Diffuse B-cell Lymphoma-Report of A Rare Case
The wood-grain pattern is distinctive enough that it usually triggers an immediate investigation. But because the condition is so uncommon, many physicians will never encounter a case in their entire career, which means recognition depends heavily on whether the clinician has seen or studied the pattern before.
Malignant Acanthosis Nigricans and the Sign of Leser-Trélat
Acanthosis nigricans is something most people associate with diabetes or insulin resistance: dark, velvety patches that appear in skin folds, particularly the neck, armpits, and groin. The benign form is extremely common and tied to metabolic conditions. But a malignant version exists, and it behaves differently. Malignant acanthosis nigricans tends to be more extensive, more rapid in onset, and may appear in unusual locations like the palms or mouth. It is most commonly associated with stomach cancer, though other tumors can trigger it. The skin changes can appear before the cancer diagnosis in about one in six cases, during the course of the disease in roughly three out of five, and after diagnosis in about one in five.5PubMed Central. Malignant acanthosis nigricans as a paraneoplastic manifestation of metastatic breast cancer When the underlying tumor is removed, the skin lesions tend to improve.
A related but debated sign is the sign of Leser-Trélat, defined as the sudden eruption of numerous seborrheic keratoses (those rough, brownish, “stuck-on” skin growths common in older adults). Because both seborrheic keratoses and cancer are common in elderly people, it can be hard to determine whether a particular surge in growths is coincidence or a genuine paraneoplastic event.6PubMed. Sign of Leser-Trélat When the sign is legitimate, it is most often associated with adenocarcinomas, particularly those in the gastrointestinal tract.7JAMA Dermatology. Malignant Neoplasms and the Leser-Trélat Sign Its frequent co-occurrence with malignant acanthosis nigricans lends support to the idea that it is a real paraneoplastic phenomenon rather than a statistical coincidence.
Sweet Syndrome
Sweet syndrome, also called acute febrile neutrophilic dermatosis, produces sudden, painful, red or purplish raised plaques on the skin, usually accompanied by fever and elevated white blood cell counts. The lesions tend to appear on the arms, neck, head, and upper body. Sweet syndrome has three clinical settings: a classical form often following infections, a drug-induced form, and a malignancy-associated form. The cancer most commonly linked to it is acute myelogenous leukemia.8PubMed Central. Sweet syndrome and its association with hematopoietic neoplasms Among patients who have both Sweet syndrome and acute myeloid leukemia, roughly a third receive both diagnoses simultaneously, another third develop the skin condition during a relapse, and about three in ten experience it during initial treatment.9PubMed Central. Sweet’s Syndrome in the Course of Acute Myeloid Leukaemia
Because the syndrome can be the first signal that leukemia has developed or returned, any new case in a patient with a blood cancer history warrants a thorough evaluation. In patients without a known malignancy, the malignancy-associated form accounts for a minority of Sweet syndrome cases, so the skin condition alone does not mean cancer is present.
When Cancer Cells Directly Invade the Skin
In some situations, the rash is not an immune byproduct of cancer but the cancer itself spreading into or originating in the skin. These cases look deceptively like common skin problems.
Breast Cancer and Carcinoma Erysipeloides
When breast cancer metastasizes to the skin, the most common manifestation is carcinoma erysipeloides, a condition that mimics a skin infection called cellulitis. It produces red, swollen, warm, tender patches that can have a distinct leading edge, spreading outward like a bacterial infection would. It develops when cancer cells spread through the lymphatic channels into the dermis. Because it looks so much like a straightforward skin infection, early cases are frequently misdiagnosed and treated with antibiotics, which of course do nothing.10PubMed Central. Carcinoma Erysipeloides: An Underdiagnosed Phenomenon of Cutaneous Metastases of Breast Cancer A “rash” on the breast that fails to respond to standard treatments should prompt further investigation, including a skin biopsy.
Paget Disease of the Breast
A related but distinct condition, mammary Paget disease is a malignancy of the nipple-areolar complex. It starts with itching and redness that looks indistinguishable from eczema. As it progresses, the nipple may crust, ulcerate, or develop discharge. It frequently masquerades as eczema, psoriasis, or even basal cell carcinoma, which delays diagnosis and treatment.11PubMed Central. Mammary Paget’s Disease Mimicking Benign and Malignant Dermatological Conditions: Clinical Challenges and Diagnostic Considerations The rule of thumb: eczema on one nipple that does not respond to standard creams deserves a biopsy, especially in someone with no prior history of eczema.
Leukemia Cutis
Leukemia cutis occurs when leukemia cells infiltrate the skin directly, producing papules, nodules, plaques, or sometimes ulcers that can appear almost anywhere on the body but tend to favor the trunk and extremities.12PubMed Central. Leukemia Cutis-The Current View on Pathogenesis, Diagnosis, and Treatment The lesions can be skin-colored, pink, red, or purple, and they vary considerably in shape and size. Leukemia cutis typically appears after a systemic leukemia diagnosis has already been made, but it can occasionally be the presenting sign. In one reported case, a patient’s first symptom was a red bump on his cheek that he assumed was an ingrown hair; it spread over his body within a month, and biopsies revealed acute myeloid leukemia.13Journal of Skin. Leukemia Cutis as the Presenting Sign of Acute Myeloid Leukemia in an HIV+ patient The clinical presentation is nonspecific enough that a biopsy is essentially the only reliable way to diagnose it.
Mycosis Fungoides and the “Great Mimicker”
Mycosis fungoides is a type of non-Hodgkin lymphoma that starts in the skin. It earns the nickname “the great mimicker” because it can look like eczema, psoriasis, contact dermatitis, or a fungal infection for years before it is recognized for what it is.14PubMed. Is it mycosis fungoides? A comprehensive guide to reaching the diagnosis and avoiding common pitfalls The disease progresses slowly through stages: flat patches, raised plaques, and eventually tumors that may ulcerate. In its earliest patch stage, it produces itchy, slightly scaly patches that can persist for years with no real change, frustrating both patients and doctors.
Diagnosis is difficult because early biopsies often look ambiguous even under a microscope. In one documented case, a patient’s mycosis fungoides was misdiagnosed as contact dermatitis, with fatal consequences.15PubMed Central. Fatal mycosis fungoides, misdiagnosed as contact dermatitis The practical takeaway here is that a persistent, treatment-resistant rash that does not quite fit any common diagnosis is worth bringing up repeatedly with your doctor, possibly including a request for a dermatology referral and biopsy. A single inconclusive biopsy does not rule out mycosis fungoides; serial biopsies over time sometimes are needed to catch it.
Rashes Caused by Cancer Treatment
A large category of cancer-related rashes has nothing to do with the cancer itself and everything to do with the treatment. If you are undergoing cancer therapy and develop a rash, it is far more likely a drug side effect than a sign that the cancer is worsening. That said, distinguishing between the two matters.
EGFR Inhibitor Rash
Drugs that block the epidermal growth factor receptor (EGFR) are used against several cancer types, including lung and colorectal cancers. Their most prominent side effect is an acne-like rash that appears in roughly two out of three patients, primarily on the face, scalp, chest, and upper back.16PubMed Central. Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR: Pathophysiology and Management The rash consists of small pustules that look like acne but behave differently and do not respond to typical acne treatments. The underlying mechanism is still not fully understood, though it involves the drug disrupting normal skin cell growth and potentially triggering an inflammatory immune response in the skin.17Annals of Oncology. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors
Here is an ironic twist: the severity of the rash from EGFR inhibitors has been associated with better cancer outcomes. Patients who develop a worse rash tend to respond better to the therapy. This creates an awkward situation where the drug is working well but making you miserable, and the rash can significantly diminish quality of life. Research shows that EGFR inhibitor rash and the itching it produces have the greatest negative impact on quality of life among all dermatologic side effects of cancer treatment.18PubMed. Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic
Immunotherapy Skin Reactions
Immune checkpoint inhibitors, used widely in melanoma and other cancers, work by unleashing the immune system against tumors. The price is that the immune system can also turn on healthy tissues, producing what are called immune-related adverse events. Skin reactions are among the most frequent of these side effects, showing up in more than a third of patients. The most common form is a maculopapular rash that resembles eczema, often accompanied by itching.19PubMed. Dermatologic Reactions to Immune Checkpoint Inhibitors More serious but rarer skin reactions, including blistering conditions, can also occur.20PubMed Central. “Skin rashes” and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management Most immunotherapy-related rashes are mild and manageable with topical steroids, but severe cases occasionally require pausing or stopping treatment.
Graft-Versus-Host Disease
After a bone marrow transplant, which is used to treat certain blood cancers, the transplanted immune cells can attack the recipient’s body. The skin is usually the first organ affected, and it is the most common site of graft-versus-host disease overall.21PubMed Central. Cutaneous Graft-Versus-Host Disease: Diagnosis and Treatment The acute form produces a rash that can range from a mild sunburn-like redness to widespread blistering. Chronic forms may cause thickened, scarred skin that restricts movement. Treatment options for steroid-resistant cases are limited, though some newer topical therapies, including vitamin D analogs, are being studied with early promising results in small trials.22PubMed Central. Prospective pilot trial of calcipotriene as a novel topical treatment for acute skin graft versus host disease
Warning Signs That a Rash Needs Investigation
Most rashes are not cancer. But certain features should prompt you to seek medical evaluation rather than wait it out or reach for over-the-counter hydrocortisone. No single skin sign is a reliable cancer detector on its own, but patterns of features matter.
- Persistence: A rash that does not respond to appropriate treatment over several weeks, or one that keeps coming back in the same location, deserves a closer look.
- Rapid onset: A sudden eruption of many lesions at once, particularly seborrheic keratoses or painful nodules, is more concerning than a gradual change.
- Asymmetry: Paget disease of the breast almost always affects one side. A unilateral eczema-like rash on a nipple in someone without eczema is a warning sign.
- Systemic symptoms: A rash accompanied by unexplained weight loss, fatigue, fever, or muscle weakness changes the clinical picture considerably.
- Unusual pattern: Wood-grain swirls, rapidly expanding dark velvety patches, or a “cellulitis” that does not respond to antibiotics all point toward conditions that warrant biopsy.
The most important practical step is a skin biopsy. Many of the cancer-related conditions described above cannot be reliably distinguished from their benign lookalikes based on appearance alone. When a rash is puzzling or persistent, a small tissue sample examined under a microscope is often the only way to get a definitive answer. If your doctor is uncertain, ask about a referral to a dermatologist with experience in complex rashes.
Why These Rashes Get Missed
The core diagnostic challenge with cancer-related rashes is that nearly all of them resemble common, harmless conditions. Mycosis fungoides looks like eczema. Carcinoma erysipeloides looks like cellulitis. Paget disease looks like nipple dermatitis. Leukemia cutis can look like anything from bug bites to drug reactions. Even experienced clinicians can be misled, particularly when the patient has no other symptoms and the rash is the only abnormality.
There is also a base-rate problem. For every patient with a persistent rash that turns out to be cancer, there are thousands whose persistent rashes are just stubborn eczema or psoriasis. Doctors appropriately try the most likely diagnoses first. The risk is that the rare but serious diagnosis gets delayed through round after round of topical steroids and antibiotics. Patient advocacy matters here: if you have been treated for a common skin condition for months without improvement, asking about alternative diagnoses and biopsy is reasonable and may be the thing that catches a problem early.
When Treatment Rashes Overlap With Disease Rashes
A particularly confusing scenario arises when someone already being treated for cancer develops a new rash. Is it a drug side effect, disease progression, an infection from an immune system weakened by chemotherapy, or an entirely unrelated skin condition? All four possibilities coexist regularly. Targeted therapies such as EGFR inhibitors and MEK inhibitors produce rashes at very high rates; in clinical trials, suppurative folliculitis was seen in 80 to 93 percent of patients across several drug types.23PubMed Central. Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions When nearly every patient on a drug gets a rash, a new skin lesion is almost certainly the drug. But “almost certainly” is not “always,” and oncologists and dermatologists sometimes need to biopsy treatment-related rashes anyway to rule out disease involvement.
The emotional toll adds another layer. Cancer patients dealing with visible skin changes report significantly diminished quality of life, and research confirms that patients on targeted therapies experience worse emotional well-being scores compared to those on conventional chemotherapy.18PubMed. Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic The rash is not just a medical footnote; it affects how patients feel about going out in public, whether they can sleep comfortably, and sometimes whether they are willing to continue their cancer treatment at all. Good supportive dermatology care during cancer treatment is not a luxury but a practical factor in treatment adherence.